Beam Therapeutics Shares Are Trading Lower After Verve Therapeutics Paused Enrollment in Its Heart-1 Clinical Trial. Verve and Beam Previously Entered a License Agreement for Access to Beam's Base Editing, Gene Editing, and Delivery Technologies
在Verve Therapeutics暂停其Heart-1临床试验的注册后，Beam Therapeutics的股价走低。Verve和Beam此前签订了许可协议，允许使用Beam的基础编辑、基因编辑和交付技术